The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
Observational Model: Case-Only Time Perspective: Prospective
Target Follow-Up Duration
Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096.
Overactive Bladder (OAB)
Drug: Fesoterodine (Toviaz)
Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Intervention: Drug: Fesoterodine (Toviaz)
* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Actual Enrollment (submitted: August 10, 2016)
Original Estimated Enrollment (submitted: September 3, 2013)
Actual Study Completion Date
Actual Primary Completion Date
May 2016 (Final data collection date for primary outcome measure)
Patients prescribed fesoterodine (Toviaz).
There are no exclustion criteria
Sexes Eligible for Study:
20 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects
Listed Location Countries
Removed Location Countries
Other Study ID Numbers
Has Data Monitoring Committee
U.S. FDA-regulated Product
IPD Sharing Statement
Pfizer CT.gov Call Center
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below: